Answers are grounded in this paper and cite their sources.
Background & Aims: The glycolytic enzyme 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 (PFKFB4) has emerged as a vital oncogene in many cancer types as a result of its metabolic function and signaling pathways. However, the effects of alternative splicing variants of PFKFB4 remain largely unexplored. Methods: kinase assays, and immunoprecipitation. Conclusions: Our study highlights the oncogenic characteristics of the novel PFKFB4-ΔEx6 variant in HCC. The direct effect of PFKFB4-ΔEx6 on AKT activation underscores its role in HCC progression and as a therapeutic biomarker for mTOR/AKT inhibitors. Impact and implications: Our study identified a non-canonical variant of PFKFB4 as a crucial activator of the AKT/mTOR signaling pathway in HCC. This discovery reveals a novel oncogenic mechanism that extends beyond the conventional role of PFKFB4 in metabolism. The PFKFB4-ΔEx6 variant enhances tumor progression and renders HCC cells sensitive to everolimus, indicating its potential as both a prognostic biomarker and a therapeutic target. Given the clinical importance of mTOR/AKT inhibitors, PFKFB4-ΔEx6 could act as a predictive marker for treatment response, paving the way for personalized therapeutic strategies in HCC. These findings provide new insights into the functional diversity of glycolytic enzymes in cancer biology and targeted therapy.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: